top of page
Endospan brings together a seasoned team of researchers, engineers and executives in the MedTech field. Backed by leading global venture groups, Endospan is focused on becoming a dominant competitor in the endovascular aortic repair market.
The Endospan platform is innovative, opening up options for repairing aneurysms and dissections in patients with anatomy previously unsuitable for endovascular therapy. The novel design of Endospan’s systems presents a true advancement when compared to traditional EVAR/TEVAR systems, enhancing endografts with gold-standard material durability, intra-procedural stability, and a shorter, simpler and less-invasive procedure.
Chief Executive Officer
Former Endologix executive with 14 years experience in R&D and global sales management demonstrating technical, sales, and marketing expertise. Innovative leader of R&D teams from concept through CE mark and IDE studies on multiple PMA products.
Click Here For Profile
General Manager IL and
Vice President of Operations
Ami Katz has over 15 years of experience in operation management, production and product management, 7 of which are in the medical field. Prior to Endospan, Ami Katz held several VP of Operations roles and led start up companies from R&D to commercial phases (CE and FDA).
Research & Development
Ian McDougall has over 20 years experience in leading teams that took products from concept, through clinical trial, and market approval in the interventional cardiology, cardiac surgery, and neurovascular fields. Prior to Endospan, Ian held director of engineering and executive roles at Aegis Innovation, Neovasc Inc., and Evasc Medical.
Sales and Marketing
Pieter Buyl has over 25 years of experience in interventional cardiology, vascular and cardiac surgery markets. Prior to Endospan, Pieter held various international sales and marketing positions at Tryton Medical,
St. Jude Medical and Boston Scientific. At Tryton Medical, a start-up company, Pieter led the sales and marketing efforts from CE mark to FDA approval including US launch.
Vice President of Clinical Affairs
Jessica Kleine joined Endospan in January 2020, giving additional depth to what was already an exciting team. She brings with her a wealth of experience in clinical research, having numerous leadership roles in diverse fields which have included the novel TENDYNE transcatheter mitral valve, devices for the treatment of peripheral artery disses, dysfunctional dialysis access, limb salvage and over 13 years of experience with class III coronary devices.
Chief Financial Officer
Gadi Divald has more than 20 years of experience as a finance and business executive, with a proven international track record in early-stage startups and private and public medium size corporates. During his career, Gadi served as CFO at Mul-T-Lock, General Manager at SanDisk Spain (Madrid, Spain), VP of Finance & Operations at msystems Asia (Taipei, Taiwan), and as CFO in other early-stage and VC backed startups (3d Signals, Upright Technologies, c2 microsystems and more). Gadi is a Certified Public Accountant (CPA) and holds a BA in accounting and business administration.
Our Medical Directors
Medical Director, NEXUS
Mario Lachat is early adopter of the Horizon and Nexus Stentgraft systems (since 2013). As cardiovascular surgeon and expert in complex open surgery and endoaortic procedures he published over 300 relevant papers. He conducted several national and international studies. He is experienced in team training and proctoring new technologies.
CAUTION: Investigational Device – Limited by United States law to investigational use. Endospan devices bear the CE marking of conformity.
bottom of page